<DOC>
	<DOCNO>NCT01035229</DOCNO>
	<brief_summary>The purpose study compare treatment RAD001 plus best supportive care ( BSC ) placebo plus BSC patient advance HCC whose disease progress sorafenib treatment intolerant sorafenib .</brief_summary>
	<brief_title>Global Study Looking Combination RAD001 Plus Best Supportive Care ( BSC ) Placebo Plus BSC Treat Patients With Advanced Hepatocellular Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Advanced liver cancer Prior systemic treatment sorafenib advance HCC disease progress sorafenib treatment , intolerant sorafenib treatment . Specifically , define : Documented radiological confirmation ( radiology scan report ) disease progression sorafenib treatment Intolerance sorafenib ( dose and/or duration ) define document sorafenibrelated grade 3 4 adverse event lead sorafenib discontinuation . NOTE : Sorafenib must last antineoplastic treatment randomization Prior local and/or hormonal therapy ( e.g. , tamoxifen ) sorafenib allow One systemic chemotherapy regimen advance HCC allow sorafenib treatment ECOG performance status â‰¤ 2 ChildPugh A Active bleeding last 28 day Prior therapy mTOR inhibitor Prior liver organ transplantation mandate systemic immunosuppression Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>randomize trial</keyword>
	<keyword>medical treatment</keyword>
	<keyword>RAD001</keyword>
	<keyword>placebo</keyword>
	<keyword>Advanced Hepatocellular Carcinoma ( HCC )</keyword>
</DOC>